Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Non-cash Items (2016 - 2022)

Spyre Therapeutics (SYRE) has disclosed Non-cash Items for 8 consecutive years, with $4.1 million as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Non-cash Items rose 1145.81% year-over-year to $4.1 million, compared with a TTM value of $4.1 million through Dec 2022, up 1145.81%, and an annual FY2022 reading of $4.1 million, up 1145.81% over the prior year.
  • Non-cash Items was $4.1 million for Q4 2022 at Spyre Therapeutics, up from $328000.0 in the prior quarter.
  • Across five years, Non-cash Items topped out at $4.8 million in Q4 2018 and bottomed at $328000.0 in Q4 2021.
  • Average Non-cash Items over 5 years is $3.3 million, with a median of $3.8 million recorded in 2020.
  • The sharpest move saw Non-cash Items plummeted 91.34% in 2021, then soared 1145.81% in 2022.
  • Year by year, Non-cash Items stood at $4.8 million in 2018, then fell by 24.09% to $3.6 million in 2019, then grew by 4.01% to $3.8 million in 2020, then tumbled by 91.34% to $328000.0 in 2021, then skyrocketed by 1145.81% to $4.1 million in 2022.
  • Business Quant data shows Non-cash Items for SYRE at $4.1 million in Q4 2022, $328000.0 in Q4 2021, and $3.8 million in Q4 2020.